These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21240620)

  • 1. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
    Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
    Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
    Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
    J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
    Masui Y; Asano Y; Takahashi T; Shibata S; Akamata K; Aozasa N; Noda S; Taniguchi T; Ichimura Y; Toyama T; Tamaki Z; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Mod Rheumatol; 2013 Mar; 23(2):323-9. PubMed ID: 22610787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
    Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
    Vanthuyne M; Blockmans D; Westhovens R; Roufosse F; Cogan E; Coche E; Nzeusseu Toukap A; Depresseux G; Houssiau FA
    Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
    Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
    J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?
    Pérez Campos D; Estévez Del Toro M; Peña Casanovas A; González Rojas PP; Morales Sánchez L; Gutiérrez Rojas AR
    Reumatol Clin; 2012; 8(2):58-62. PubMed ID: 22317852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
    Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
    Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
    Kundu S; Paul S; Hariprasath K; Agarwal R; Ghosh S; Biswas D
    Indian J Chest Dis Allied Sci; 2016; 58(1):7-10. PubMed ID: 28368564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
    Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.
    Schnabel A; Reuter M; Gross WL
    Arthritis Rheum; 1998 Jul; 41(7):1215-20. PubMed ID: 9663478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options for systemic sclerosis related interstitial lung diseases.
    Mouthon L; Bérezné A; Guillevin L; Valeyre D
    Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.